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Abstract
 
The immune response to HIV-1 in patients who carry human histocompatibility leukocyte an-
tigen (HLA)-B27 is characterized by an immunodominant response to an epitope in p24 gag
(amino acids 263–272, KRWIILGLNK). Substitution of lysine (K) or glycine (G) for arginine
(R) at HIV-1 gag residue 264 (R264K and R264G) results in epitopes that bind to HLA-B27
poorly
 
. 
 
We have detected a R264K mutation in four patients carrying HLA-B27. In three of
these patients the mutation occurred late, coinciding with disease progression. In another it oc-
curred within 1 yr of infection and was associated with a virus of syncytium-inducing pheno-
type. In each case, R264K was tightly associated with a leucine to methionine change at residue
268. After the loss of the cytotoxic T lymphocyte (CTL) response to this epitope and in the
presence of high viral load, reversion to wild-type sequence was observed. In a fifth patient, a
R264G mutation was detected when HIV-1 disease progressed. Its occurrence was associated
with a glutamic acid to aspartic acid mutation at residue 260. Phylogenetic analyses indicated
that these substitutions emerged under natural selection rather than by genetic drift or linkage.
Outgrowth of CTL escape viruses required high viral loads and additional, possibly compensa-
tory, mutations in the gag protein.
Key words: human immunodeficiency virus • immune escape • selection • CD8
 
1 
 
T 
lymphocyte • phylogenetic analysis
 
Introduction
 
The ability of HIV to adapt to changes in its environment
through mutation of its genome is well described. Evidence
from the simian immunodeficiency virus (SIV)
 
1
 
-macaque
model of immunodeficiency virus pathogenesis indicates
that CD8
 
1
 
 T cells can control retrovirus replication (1, 2)
and that SIV evolves to escape the CD8
 
1
 
 CTL response (3,
 
J
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 CAC, combination antiretroviral chemo-
therapy; SI, syncytium-inducing; SIV, simian immunodeficiency virus;
w/t, wild-type.
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4). These data add substantial support to earlier studies in
humans which demonstrated that HIV-1 mutants can es-
cape CTL responses (5–8). Viral escape from CTLs may
occur rapidly during primary infection, or late in the dis-
ease as features of AIDS appear, but the constraints on the
evolution of escape mutants are unclear.
In patients who carry HLA-B2705, the HIV-specific
CTL response, during the chronic phase of infection, is
usually characterized by an immunodominant response to
an epitope in the core protein, p24 (amino acids 263–272,
KRWIILGLNK; references 7 and 9). The interaction of
the arginine (R) residue at position 2 of this and other
HLA-B2705–restricted epitopes with the B pocket of the
HLA-B2705 plays a crucial role in stabilizing the MHC–
peptide complexes (9–13). Substitution of either lysine (K)
or glycine (G) for arginine (R) at gag residue 264 (R264K
and R264G) results in an epitope that binds poorly to
HLA-B2705, thus forming unstable complexes (7, 14).
In two previously described patients, the mutation K
(AAA) for R (AGA) at residue 264 (R264K) occurred late
in the infection and coincided with disease progression
(7). This mutation could have enabled viral escape from
CTLs. Another nonsynonymous mutation, AGA to GGA
(R264G), has not been detected in patients, but was engi-
neered into the LAI strain of HIV. This synthetic mutant
virus was replication competent in vitro
 
 
 
(14). As viral turn-
over in untreated HIV-infected patients is high (15, 16)
and HIV reverse transcriptase has an error rate of 10
 
2
 
4
 
 base
incorporations (17–19), Nietfield et al. argued that R264G
should be preferentially selected if CTLs exerted a signifi-
cant selection pressure on the virus (14). However, this se-
quence is absent from the database (20), arguing against
CTLs being important in control of virus replication (14).
The epitope is within a structurally important region of
p24 which is involved in the conformational multimeriza-
tion of p24 during capsid formation (21). As this protein
structure must be maintained, few amino acid substitutions
within or near the HLA-B2705–restricted epitope are
likely to be tolerated.
Here we describe five HIV-infected patients with HLA-
B2705 in whom the appearance of mutations at R264 was
observed. This selection occurred both after primary infec-
tion and during late HIV disease. When CTL selection
pressure was lost, partial reversion to wild-type (w/t) virus
sequence occurred.
 
Materials and Methods
 
Patients.
 
HIV-1–infected patients attending clinics for the
first time were HLA typed by sequence-specific primer methods
(22). Patients with HLA-B2705 had PBMCs taken whenever the
patient attended clinic. Patients without HLA-B27 who were re-
cruited to other studies had samples collected on at least one oc-
casion. All studies were approved by the appropriate local Re-
search Ethics committees.
 
Isolation of PBMCs.
 
PBMCs were isolated from heparinized
blood by standard density centrifugation on Lymphoprep (Ny-
comed). Cells were washed twice in RPMI 1640 (Sigma-Aldrich)
and then either cryopreserved or set up in culture.
 
Sequencing of Cell-associated Viral DNA.
 
2–3 
 
3
 
 10
 
6
 
 PBMCs
were resuspended in RPMI 1640 supplemented with 10% FCS,
penicillin/streptomycin (GIBCO BRL), and glutamine (GIBCO
BRL), and stimulated for 36–48 h with a 1:200 dilution of PHA
(Murex). DNA was isolated from PBMCs using the Puregene kit
(Gentra Systems) and stored at 
 
2
 
20
 
8
 
C. A nested PCR was per-
formed as described which resulted in the amplification of a 335-
bp sequence from p24 (7). The products were ligated into a thy-
midine/adenosine (T/A) vector and used to transform competent
cells (Invitrogen). Positive colonies were identified by blue/white
selection and grown up over night in Luria-Bertani (LB) media in
the presence of ampicillin. Plasmid DNA was isolated using
either QIAGEN or Hybaid miniprep kits and cycle sequenc-
ing reactions were performed using 7-deaza-dGTP (Amersham
Pharmacia Biotech) and Cy5-labeled T7 primer (Amersham
Pharmacia Biotech). Reactions were loaded onto a 5.75% acryl
amide gel and run out on an automated sequencer (Amersham
Pharmacia Biotech) and analyzed using the ALF/WIN Express
software. A minimum of 20 clones were sequenced at each time
point in the HLA-B27–positive patients.
Viral subtype was determined using “HIV subtyping using
BLAST” software available on the Los Alamos HIV sequence
data base web site (http://hiv-web.lanl.gov/). p24 sequence data
from each patient were compared with several reference se-
quences of each subtype, scored for similarity to each, and a sub-
type allocated.
 
Phylogenetic Analysis.
 
Phylogenetic trees were reconstructed
using the maximum likelihood (ML) available in PAUP
 
*
 
 (v4)
provided by D.L. Swofford (Sinauer Associates, Sunderland,
MA). The HKY85 model of DNA substitution was used in all
cases with the maximum likelihood transition/transversion ratio
(Ts/Tv) and alpha (
 
a
 
), the shape parameter of a discrete approxi-
mation to a gamma distribution of rate heterogeneity among sites
(here assumed to contain eight rate categories), determined using
an iterative procedure in which these parameters were continu-
ally adjusted until the tree of highest likelihood was found. These
parameter values are available from the authors on request.
 
Population Genetic Analysis.
 
The effective population size (
 
N
 
e
 
)
of HIV-1 within patients was estimated by rearranging the rela-
tion 
 
u
 
 
 
5
 
 2
 
N
 
e
 
m
 
, where 
 
u
 
, a measure of genetic diversity assuming
neutral evolution, was estimated using a Metropolis-Hastings
sampling method (program Fluctuate, v1.3; reference 23), and the
mutation rate, 
 
m
 
, was set to 3 
 
3
 
 10
 
2
 
5
 
 per site, per generation (24).
 
Viral Loads and CD4
 
1
 
 Cell Counts.
 
Viral loads were deter-
mined on sterile plasma separated within 6 h of collection into
EDTA, and stored at 
 
2
 
70
 
8
 
C by the Amplicor kit (Roche).
CD4
 
1
 
 counts were determined by standard methodology.
 
HLA Class I Tetramers.
 
HLA-B27, HLA-A2, HLA-A11,
HLA-B35, HLA-B7, and HLA-B8 tetramers were synthesized
as reported previously (22).
 
 
 
The following HLA class I–pep-
tide complexes were synthesized:
 
 
 
B2705 (C67S) gag 263–272
(KRWIILGLNK), B2705 gag 263–272 (KRWIIMGLNK), A201
gag 77–85 (SLYNTVATL), A201 pol 476–484 (ILKEPVHGV),
B35 nef 78–85 (VPLRPMTY), B35 gag 260–268 (PPIPVGDIY),
B35 gp120 42–52 (VPVWKEATTTL), B7 nef 128–137 (TPG-
PGVRYPL), B7 gag 148–156 (SPRTLNAWV), B8 gag 24–31
(GGKKKYKL), B8 nef 89–97(FLKEKGGL), B8 nef 13–20
(WPTVRERM), A11 pol 325–333 (AIFQSSMTK), and A11 nef
75–86 (QVPLRPMTYK). For staining, PBMCs were resus-
pended in PBS and 1% BSA, washed, and then incubated for 60
min at 4
 
8
 
C in the presence of the tetramer. The cells were then
washed twice in PBS plus 1% BSA and then incubated for another
20 min at 4
 
8
 
C in the presence of an FITC-conjugated CD8 anti-
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body (Dako). Cells were washed twice as above and then resus-
pended in PBS plus 1% BSA plus 4% formaldehyde and stored at
4
 
8
 
C for up to 48 h before analysis on a FACScan™ (Becton Dick-
inson) using CELLQuest™ (Becton Dickinson) software. Lym-
phocyte gates were set on forward versus side scatter. CD8
 
1
 
 gates
were set by isotype control staining and cutoffs for positive stain-
ing were set by staining with an irrelevant tetramer.
 
Bulk Culture and Cell Lines.
 
Bulk culture and cell lines were
set up as detailed previously. Chromium release assays were per-
formed as detailed previously (7, 9).
 
Online Supplemental Material.
 
For each patient described, the
date of identification, viral load, CD4
 
1
 
 cell count, and the per-
centage of total sequences at each time point with substitutions
are shown in Table SI. CTL escape mutations are shown in
bold. Available at http://www.jem/org/cgi/content/full/193/3/
375/DC1.
 
Results
 
HLA-B27–positive Patients
 
12 HIV-infected patients with HLA-B27 were studied.
All were male. Eight had acquired HIV through sexual
contact. The others were hemophiliacs who acquired HIV
from blood products (Table I). Three were studied during
primary infection, five during the asymptomatic phase of
the disease, and four during late stage disease. p24 se-
quences from each patient were subtype B.
 
Selection of R264K and R264G Mutants
Acute Primary Infection.
 
Patient 777 was identified 14 d
after a high risk exposure with fever, headache and esoph-
ageal candidiasis. His HIV RNA was 
 
.
 
10
 
6
 
 copies/ml of
plasma. He declined antiretroviral therapy. Viral loads and
CD4
 
1
 
 counts are shown in Fig. 1. During symptomatic in-
 
fection viral sequences were w/t at position 264 (R264)
and showed methionine (M), rather than leucine (L) at po-
sition 268 (Fig. 1 a, and online supplemental Table SI). 28
wk later, his virus contained a mixture of both M268 and
L268, but retained R264 in all sequences. 52 wk after ac-
quiring infection, 96% of his viral sequences carried the
R264K sequence (1/25 had R264I) and all had M268.
Combination antiretroviral chemotherapy (CAC) was in-
stituted at this visit because of persistent viremia and the
development of a virus with a syncytium-inducing pheno-
type (SI). Viremia was better controlled after therapy and a
mixed population of viral sequences was detected (Fig. 1 a,
and online supplemental Table SI). Throughout the period
of observation, this patient had a robust HLA-B27–restricted
immunodominant CD8
 
1
 
 T cell response to p24 gag
(263–272) as detected by tetramer staining (Fig. 1 a).
Patients SC8 and SC40 were also identified during pri-
mary infection with seroconversion illnesses and both were
treated with CAC very early in their infections (online sup-
plemental Table SI). Both have HLA-B2705, but did not
select R264K during the study period. SC8
 
 
 
had a reduc-
tion of viral load to 
 
,
 
400 copies/ml by day 50. This was
maintained for 2.1 yr. Viral sequences remained w/t with
L268 (online supplemental Table SI). In SC40, viral load
was reduced to undetectable levels 80 d after initial presen-
tation and remained 
 
,
 
1,000 copies/ml thereafter. In this
patient, virus sequences were w/t with L268. Immuno-
dominant HLA-B27–restricted CD8
 
1
 
 T cell responses to
p24 gag (263–272), as defined by enzyme-linked immuno-
spot assay and tetramer staining, were documented in both
these patients (25).
 
Late Stage Infection.
 
Patient SW presented with 
 
Pneu-
mocystis carinii
 
 pneumonia, and was subsequently found to
be HIV seropositive with a high viral load and a low CD4
 
1
 
cell count. In the first sample available for sequencing, col-
lected 12 wk after initial presentation, all proviral sequences
showed the R264K mutation and M268 (Fig. 1 c). A
HLA-B27–restricted T cell response to the M268 variant
peptide was detectable by tetrameric staining (0.68% of
CD8
 
1
 
 cells) at this and the next time point (0.28% of
CD8
 
1
 
 cells) but not later (Fig. 1 c). No HLA-A11– or
HLA-B35–restricted responses were detected in this patient
at any time by tetramer staining or chromium release assays
performed on bulk cultures. When effective antiretroviral
therapy was started 16 wk after presentation, the viral load
fell and the R264K mutation persisted.
As described previously (7), the hemophiliac patients 007
and 025 had w/t epitope sequences with R264 and L268;
however, L268M occurred relatively early in the course of
infection (online supplemental Table SI). Subsequently,
each developed the R264K mutation as disease progressed
with increasing viral loads and falling CD4
 
1
 
 counts (7; on-
line supplemental Table SI, and Fig. 1). Patient 007 had ex-
hibited a sustained immunodominant CTL response to the
HLA-B27–restricted gag 263–272 epitope (7, 9, 26). This
was confirmed by tetramer staining but responses became
undetectable as measured by tetrameric complexes, bulk
culture, and peptide generated cell lines 1 yr after the rise
 
Table I.
 
Summary of Patient Characteristics
 
Risk
group
HLA
Disease state
when identifiedIdentifier Sex A B
007 M Hph 1, 32 27, 44 Asymptomatic
049 M Hph 3, 3 27, 39 Asymptomatic
422 M Hs 24, 31 27, 57 Asymptomatic
868 M Hs 2, 22 27, 35 Asymptomatic
025 M Hph 3, 10 7, 27 Asymptomatic
CW M Hph 1, 2 8, 27 AIDS
MH M Hph 2, 32 7, 27 AIDS
SW M Hs 11, 32 27, 35 AIDS
RT M Hs 1, 2 8, 27 AIDS
777 M Hs 1, 3 27, 35 Primary infection
SC8 M Hs 2, 3 27, 39 Primary infection
SC40 M Hs 1, 30/31 27, 35 Primary infection
Hs, homosexual contact; Hph, hemophiliac exposed to infected blood
products.
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to fixation of the R264K mutation (Fig. 1 b). Patient 025
also had detectable HLA-B27 gag-specific CTLs before the
appearance of the R264K mutation.
Because of disease progression, patient 007 was com-
menced on dual nucleoside therapy, the only drug therapy
available at the time. This had a transient effect on viral load
and little effect on his low CD4
 
1
 
 count. Later, CAC was
instituted but this had no effect on viral load or CD4
 
1
 
 cell
count (Fig. 1 b). When the viral load was high and the CTL
response was undetectable, the epitope sequences partially
reverted from K264 to w/t (K264R). In the sequences
where this occurred, but not in the escape sequences, there
was an increasing frequency of the other reversion mutation
M268L (online supplemental Table SI, and Fig. 1 b).
 
Patient RT presented with 
 
Pneumocystis carinii
 
 pneumo-
nia and was then found to be infected with HIV. He re-
ceived 8 wk zidovudine monotherapy, which resulted in a
transient increase in CD4
 
1
 
 cell number, but this drug
was stopped because of side effects. HLA-B27 gag epitope
sequences 48 wk after AIDS was diagnosed were uni-
formly R264 and L268. 58
 
 
 
wk after diagnosis, zidovudine
and didanosine, introduced because of falling CD4
 
1
 
 cell
counts, resulted in a transient rise in CD4
 
1
 
 cell numbers. 6
mo later, a protease inhibitor was added resulting in a sus-
tained rise in CD4
 
1
 
 cells and reduced viral loads. Approxi-
mately 20 mo after presentation the R264G mutation was
found in all sequences (Fig. 1 d). This mutation was always
associated with L268, and a E260D mutation in the NH
 
2
 
-
Figure 1. Time course of four subjects develop-
ing nonbinding mutations: (a) 777, (b) SW, (c)
007, and (d) RT. In each, the top panel shows
CD41 count (left axis) and HLA B-27 tetramer
staining (right axis); the middle panel shows viral
load (log RNA copies/ml); and the bottom panel
shows the percentage of clones with each variant
epitope sequence. Top panels: filled boxes, CD41
T cell count; open triangles, percentage of CD81
cells staining with M268 variant peptide B27 tet-
ramer; open diamonds, percentage of CD81 cells
staining with L268 variant peptide B27 tetramer.
Double-headed arrows indicate period during
which fresh killing was detected of peptide-pulsed
autologous targets. Middle panels: closed circles,
viral load log10 copies of HIV RNA/ml plasma.
Periods of mononucleoside analogue therapy
(MT), dual nucleoside analogue therapy (DT), and
combination therapy with dual nucleoside ana-
logues and a protease inhibitor (CAC) are indicated
by double arrow headed lines. Bottom panels:
white bars, percentage of viral DNA sequences
with R264 M268; gray bars, percentage of viral
DNA sequences with E260 R264 L268 (w/t);
black bars, percentage of viral DNA sequences
with K264 M268; horizontal stripe, percentage of
viral DNA sequences with K264 L268; left to right
downward hatch, percentage of viral DNA se-
quences with D260 G264 L268; and right to left
downward hatch, percentage of viral DNA se-
quences with another mutation at 264.
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terminal flanking region of the epitope, at this and at all
subsequent time points. CD8
 
1
 
 T cell responses to the w/t
epitope were detected by tetrameric staining at weeks 28
and 48, but disappeared when the mutant was present (Fig.
1 d). Tetramer staining for HIV-specific CD8
 
1
 
 T cells re-
stricted through HLA-A2 and HLA-B8 was not found at
any time.
Three other patients studied had progressive disease but
no mutation at R264 was found during the course of the
study. Patients CW and MH were recruited after an AIDS
diagnosis. Patient CW has never received antiretroviral
therapy but has had relatively stable clinical disease with an
intermediate viremia (online supplemental Table SI). Pa-
tient MH commenced CAC shortly after being identified
and since then has had a stable CD4
 
1
 
 cell count and unde-
tectable viral load (online supplemental Table SI). Neither
had HIV-specific CD81 T cells detected either by tradi-
tional CTL assays or by tetramer staining with HLA-A2,
HLA-B8, HLA-B7, or HLA-B27 constructs at any time
point studied (data not shown). Both have proviral se-
quences that are w/t at the HLA-B27 gag epitope with
L268. Patient 868 has been followed for over 10 yr. Over
the last 2–3 yr he has had progressive disease and tran-
siently effective dual nucleoside therapy, followed by CAC
with a sustained virological response. Initially, he had ro-
bust CTL responses restricted through: HLA-A2 to gag
(77–85) but not pol epitopes, HLA-B35 to nef (75–82),
and HLA-B27 to gag (263–272; dominant response). After
CAC, these responses were initially maintained but by 6
mo became undetectable by any technique. All sequences
had w/t virus with M268. Despite high viral turnover be-
fore initiation of dual nucleosides and when therapy failed,
mutation at position 264 was not detected (online supple-
mental Table SI).
Long-term Nonprogressors
Two patients (049 and 422) fulfil criteria for long-term
nonprogression (at least 10 yr after diagnosis with CD41
counts .500 cells/ml; online supplemental Table SI). Both
have CD81 T cells that recognize gag 263–272 restricted
through HLA-B27 (data not shown), but there is no evi-
dence for escape. Both have L268 and have been shown to
have responses to HIV mediated through other HLA class I
alleles, although in each case the HLA-B27 response ap-
pears to be dominant (reference 7, and Kelleher, A.D., un-
published results).
Context of Mutations at Codon 264
In each patient when the R264K mutant was first de-
tected, a majority of the preceding viruses sampled had
M268. R264 can be found with either M268 or L268,
whereas K264 is strongly associated with M268. In only 2
out of 329 sequences were K264 and L268 found together.
In neither case was this sequence detected in subsequent
samples. Even in populations containing mixtures of R264
and K264, the latter always segregated with M268, whereas
R264 associated with both M268 and L268 (Table II).
Similarly, the R264G mutation appears only in the context
of the amino acid residues L268 and E260D.
Mutations in This Region of p24 in
HLA-B27–negative Patients
All gag sequences derived from HLA-B27–negative pa-
tients studied in our laboratories, which included this re-
gion of p24, were analyzed. 24 HIV-infected patients had
subtype B p24 sequence data available for analysis from at
least one time point. 15 of these were patients with re-
cently acquired infection and 2 of these were sequenced on
two occasions 18–20 mo apart. Nine others had chronic
disease, with infections of 4–11 yr duration (median dura-
tion: 6 yr, median CD4 count 300 cells/ml, median viral
load 3.5 3 104 copies of viral RNA/ml) and were se-
quenced on 2–5 occasions during that time. Two of these
patients had commenced therapy with CAC for high viral
loads and low CD4 cell counts at the time of sequencing.
An average of 15 clones was assessed at each time point. 1
of these 24 patients, a patient with primary infection, had
K264 in 7/7 clones sequenced at a single time point before
seroconversion. In this subject, K264 occurred in associa-
tion with T280S and R286K in all sequences. These muta-
tions at codons 280 and 286 are not seen in any of the four
HLA-B27–positive patients with R264K and L268M, but
are commonly seen in subtype A viruses (20). In all the re-
maining 483 clones derived from the other HLA-B27–
negative patients, R264 was uniformly detected. One of
the HLA-B27 negative patients had M268 in all sequences
at each of two time points and two of these patients had
D260 in a majority of sequences from several time points.
These data, along with a review of the Los Alamos database
(Table III), indicate that R264K mutation occurs rarely in
subtype B viruses.
Phylogenetic Analysis
Phylogenetic trees were constructed for the viral se-
quences obtained from three of the patients: RT, 007,
and 777 (Fig. 2, a–c) to study the evolutionary processes
contributing to the accumulation of mutations clustered
around codon 264. In the tree constructed for patient RT,
there is a long branch separating the sequences sampled 0.9
yr after enrolment from those collected at later time points
(2.4–2.8 yr after enrolment). Two amino acid changes have
occurred on this branch: E260D and R264G. It is striking
Table II. 2 3 2 Table Demonstrating the Association R264 or 
K264 with either M268 or L268 in All Sequences Derived from Time 
Points Where a Mixture of Clones Expressing either R264 or K264 
Were Found
Clones R264 K264 Total
L268 27 0 27
M268 32 81 113
Total clones 59 81 140
Fisher’s exact P value , 0.0001. Time points used in this analysis were:
777, 1.0, 1.3, and 2.4 yr; 007, 12.7, 12.8, 12.9,14.5, 15.0, 15.2, and 15.4
yr; SW, 1.1 yr.
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that these two changes are in such close proximity in the
amino acid sequence and that they are fixed in all later sam-
ples (Fig. 1 d, and online supplemental Table SI). This sug-
gests that either both represent escape mutants, or that one
is favored by selection and that the other has been pulled to
fixation by genetic linkage.
The action of positive selection at codon 264 is sup-
ported by an analysis of the numbers of synonymous (dS)
and nonsynonymous (dN) substitutions per site in this
codon. In patients RT, 007, and 777 combined, 11 non-
synonymous and 0 synonymous substitutions are observed
at codon 264. This bias toward nonsynonymous substitu-
tions is significantly more than expected by chance alone
(P 5 0.021 in a x2 test weighted for the different rates of
substitution among bases) showing that dN . dS for this
codon as expected under positive selection. In other words,
codon 264 does not evolve quickly simply because it is
subject to weaker selective constraints.
Support for positive selection also comes from a popula-
tion genetic analysis of diversity. If, for example, the fixa-
tion of R264G in patient RT occurred between 0.9 and
2.4 yr after enrolment, as is compatible with the phyloge-
netic analysis, then this fixation event took no more than
z18 mo. For this process to occur by genetic drift alone
would require an Ne of only z100, assuming that the HIV
generation time is 2.6 d (16) and that fixation of neutral
mutations takes on average 2Ne generations (27). However,
if Ne is estimated directly from the sequence data of patient
RT using a neutral measure of genetic diversity (u), then
the average value of Ne across time points is z800 (u values
from 0.025 to 0.076). Consequently, although the effective
population size in patient RT is small, as might be expected
to be the case after a selective sweep, it is still not small
enough to allow fixation of a neutral mutation by genetic
drift in such a short time period.
The phylogenetic analysis also supports the selection of
R264K in patients 007 and 777. In patient 007, all se-
quences present at 11.8 yr after diagnosis were R264, but
by 33 mo later (14.5 yr after diagnosis) all sequences were
K264 (Fig. 2 b). Interestingly, R264 then reappeared after
antiviral therapy, remained in the population for the last
year of sampling, and reached a frequency of 25%. The
Table III. Summary of All Examples of R264K or L268M and Their Associated Amino Acid Changes in the Immediate Region of the gag 
HLA-B2705–restricted Epitope Seen in 529 gag Sequences from the Los Alamos Database (Reference 20)
Virus Clade Origin 260 264 268 272
Consensus B G E I Y K R W I I L G L N K I V R
WEAU 160
AF069140a B USA 2 2 2 2 2 2 2 2 2 M 2 2 2 2 2 2 2
GA18 B Spain 2 2 2 2 2 2 2 2 2 M 2 2 2 2 2 2 K
CI51 A Ivory Coast 2 2 2 2 2 K 2 2 2 2 2 2 2 2 2 2 2
LBV2-3 A Gabon 2 D 2 2 R K 2 2 2 2 2 2
AF110979b, C Botswana 2 D 2 2 2 2 2 2 S M 2 2 2 2 2 2 2
G109 D Gabon 2 2 2 2 2 K 2 2 2 M 2 2 2 2 2 2 2
Consensus O 2 D 2 2 R 2 2 2 V 2 2 2 2 2 M 2 K
ANT70Cc O Cameroon 2 D 2 2 R K 2 2 V 2 2 2 2 2 M 2 K
CA9 O Cameroon 2 D 2 2 R K 2 2 V F 2 2 2 2 L 2 K
BCF02B O Cameroon 2 2 2 2 W K 2 2 V 2 2 2 2 2 L 2 K
AF009015d, U Cameroon 2 D 2 2 R K 2 2 V 2 2 2 M 2
AF009019 U Cameroon 2 D 2 2 S K 2 2 V 2 2 2 Q M 2 N
AF009016e, U Cameroon 2 D 2 2 R K 2 2 V 2 2 2 2 L 2 K
AF006857 U Uganda 2 ? 2 2 R K 2 2 2 2 2 ? 2 2 2 2 2
AF006924 U Uganda 2 D 2 2 2 K 2 2 2 2 2 2 2 2 2 2 2
HIV90CF402 AE Thailand 2 2 2 2 2 K 2 2 2 2 2 2 2 2 2 2 2
VI354 AG Gabon 2 K 2 2 2 K * 2 2 2 2 2 2 2 2 2 2
HIV224190 B/E Thailand 2 D 2 2 2 Q 2 2 2 M 2 2 2 2 2 2 2
HIV224194 B/E Thailand 2 2 2 2 2 2 2 2 M 2 2 2 2 2 2 2
HIV224196 B/E Thailand 2 D 2 2 2 2 2 2 2 M 2 2 2 2 2 2 2
*, stop codon; other sequences have stop codon at 793 (e.g., accession no. L11970/U43172) and other pseudogenes have been excluded from the
analysis. U, untyped. Identical sequences, in this region, are seen in the following viruses: aPH136, from the Philippines and BZ190 from Brazil,
bAF110980 and 110981 from Botswana, cMVP5180, BCF01B, BCF03B, BCF07B, BCF08B, BCF06B,BCF11B, AF001966, AF001967, and
AF001969 from Cameroon, AF001970, AF001971, AF001972, and AF001973, from Equatorial Guinea, and VI686 from Gabon, dAF009018 from
Cameroon, and eAF009024 from Cameroon.
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phylogenetic tree reveals that the main source of this virus
is persistence of a variant bearing R264, as those sequences
which bore R264 later are clustered with those earlier sam-
ples which carry R264. However, it is also apparent from
the phylogenetic tree that at least one K264R reversion
mutation has occurred (Fig. 2 b).
A similarly complex evolutionary picture is seen in pa-
tient 777. In this patient, the R264K mutation may have
Figure 2. Maximum likelihood phylogenetic trees depicting the evolutionary re-
lationships of viruses from patients (a) RT, (b) 007, and (c) 777. The tree is un-
rooted but the direction of mutations can be inferred by assuming that the oldest
sampled sequences are ancestral. All branch lengths are drawn to scale. The labels on
each branch correspond to the time point at which the viral sample was taken (years
after diagnosis), followed by the amino acid (single letter code) found at positions
260, 264, and 268, respectively. The positions of all putative changes involving
amino acids E to D at position 260, R and K at position 264, and M to L at position
268 are indicated with arrows. Note that designation of amino acid changes is diffi-
cult inpatients 007 and 777 because viruses from the first sampling time point do not
form a single group and are dispersed across the phylogeny. Genbank accession
numbers for sequences used to construct phylogenetic trees are available from Gen-
bank/EMBL/DDBJ under accession nos. RT, AF319258–AF319310; 007,
AF319174–AF319257; and 777, AF319311–AF319396.
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arisen four times, but never reaches fixation (i.e., 100% fre-
quency), perhaps because antiviral therapy was given after
that time which altered the selection pressure on viral evo-
lution. R264 then rises in frequency later on in infection
seemingly because of the persistence of lineages with R264
across several time points.
The phylogenetic analysis also provides strong support
for the compensatory relationship between the mutations at
positions 264 and 268. In both patients 007 and 777, L268
only occurs in association with R264 (Fig. 2, b and c).
Moreover, the phylogenetic analysis reveals that changes at
amino acid positions 264 and 268 occur on different
branches of the tree, indicating that they are independent.
Such observations suggest that although L268 and R264
are intimately related, they are not in direct linkage; the rise
of M268L is not simply due to it being linked to a selec-
tively favored K264R virus. For patient 777, the M to L
change has actually occurred twice independently.
Discussion
This study defines some of the complex requirements for
the evolution of CTL escape mutants at a locus in a highly
conserved HIV protein. We have described five HLA-B27
carrying HIV-infected patients, four of whom have ac-
quired the same (R264K) escape mutation in gag. In a fifth
patient an alternative mutation (R264G) was seen. We
have shown that the R264K mutation is strongly associated
with a second change L268M and that the acquisition of
this doubly modified epitope does not appear to result from
simple linkage between the mutations at sites 264 and 268.
Escape occurred both early and late in HIV disease but re-
quired high viral replication and compensatory mutations
nearby in HIV-1 p24. Frequent selection of the same mu-
tations, which are uncommon in the database and HLA-
B27–negative subjects, and the rapidity with which they
are fixed within patients, strongly implies selection by
CTLs specific for the epitope.
The mutability of HIV and its ability to adapt to envi-
ronmental pressures has been well demonstrated by the
rapid emergence of drug resistance mutations in reverse
transcriptase and protease (for reviews, see references 28
and 29). In the case of resistance to protease inhibitors, mu-
tations that appear to have no direct effect on the active site
of the enzyme have been described. These appear to com-
pensate for critical mutations within the active site itself
(30–32).
Evidence supporting a role for CTLs in the control of
HIV includes: depletion of CD81 cells results in more
rapid progression of SIV-related disease in macaques (1, 2),
the appearance of HIV-specific CTLs at primary infection
coincides with control of viremia (25, 33, 34), and CTL es-
cape mutations allow immune evasion by HIV early in dis-
ease (5, 6). These data indicate that CTLs can exert a signif-
icant selective force upon the virus. Later in the disease, the
mutability of the virus allows it to generate escape muta-
tions rapidly after artificial perturbations of the steady state
which resulted in a highly focused CTL response (8). In
animals infected with identical strains of SIV, nonsynony-
mous mutations in nef and env accumulate exclusively
within antigenic sites subject to CTL pressure (3).
These studies suggest that several conditions need to be
met to permit the evolution of CTL escape mutants at the
HLA-B27 gag epitope. High viral turnover appears to be a
requirement whether escape occurs early in the disease as
with patient 777, or late in the disease as with patients 007,
RT, SW, and 025. In those treated effectively and early in
primary infection, escape did not occur for as long as 2.1
yr. Long-term nonprogressors and patient CW, whose viral
load was constant at 4.5 logs, did not develop very high
levels of viral turnover and did not generate escape mu-
tants.
Why do these mutations, which arise in an epitope that
is the target of a highly focused CTL response, not occur
earlier in the disease? There are several possible explana-
tions. These mutations may only arise in certain viral
strains. SI phenotypes of HIV-1 are more pathogenic and
usually occur later in the disease (35–37). The only patient
who had early escape developed an SI virus early in the in-
fection. Those whose virus escaped late in infection are
likely to have had SI virus. SI virus is not susceptible to in-
hibition by b-chemokines released from CD81 T cells
(38). In the absence of soluble factor inhibition, SI virus
faces an immune selection pressure more clearly restricted
to the CTL response than non-SI virus, and thus genera-
tion of escape mutants to lytic activity of CD81 T cells may
be favored.
A second explanation for constraint on evolution within
gag involves the structure and function of this protein. The
HLA-B27 epitope lies embedded in the NH2-terminal do-
main of the p24 capsid protein. Evidence for the need to
conserve structure in this region of the protein comes from
several sources. First of all, most mutations in this area re-
sult in nonviable virus (14), and deletion mutants indicate
that this region is necessary for the conformational changes
that allow p24 to form functional capsid after p24 multi-
merisation (21, 39). Second, the crystal structure of the
NH2-terminal domain of p24 reveals that the epitope and
its NH2-terminal flanking regions lie within helix 7 (amino
acid residues 258–276), one of five helices within the NH2-
terminal domain that form a coiled coil structure (40–42).
Residues 260, 264, and 268 all lie on the same aspect of he-
lix 7 (Fig. 3 a). Furthermore, the packing of molecules into
crystals of the NH2 terminus of p24 is dependent on the
formation of two interfaces, and one of these interfaces is
formed by parallel packing of helix 7 from adjacent mole-
cules. Residues 264 and 268, along with 271 and 275, play
a role in the formation of this interface, and R264 and
L268 lose significant accessible surface area (Fig. 3 b). In
this structure, the aliphatic portions of the two R264 side
chains are in van der Waals contact with each other and
guanidium groups participate in a charged interaction with
the side chains of E260 (41). Moreover, a model of core
particle assembly predicts that antiparallel interactions be-
tween helix 7 and helix 2 are the basis for NH2-terminal
dimerization and that helix 7 plays a role in the association
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of these dimers to form arrays of capsid molecules before
the formation of the mature capsid (43). Taken together,
these findings indicate that this region plays an important
role in capsid self-association and conformational assembly.
Furthermore, although this area is not the primary site of
p55 association with cyclophilin (44), deletions in this area
can abrogate cyclophilin binding to p24 (45). Therefore,
mutations in this area are likely to interfere with viral as-
sembly and thus impair fitness. Accommodation of a new
mutation in one part of this structure may require at least
one compensatory mutation.
The results presented here indicate that in subtype B vi-
ruses, if the R264K mutation is to be tolerated, a L268M
mutation is preferred. Furthermore, after development of
the escape mutation, the reversion of methionine to w/t
leucine at position 268 (M268L) only occurs after the reap-
pearance of arginine at position 264. In subtype B viruses
M268 is uncommon, reported in only 3 out of 57 subtype
B p24 sequences in the Los Alamos data base (20; Table
III). The K264 mutation is not reported in subtype B vi-
ruses. In subtype D viruses, where K264 is present in a mi-
nority of sequences, there is an accompanying M268 muta-
tion (Table III). However, there are three p24 sequences
(CI51, HIV90CF402, and AF006924) in the database
where K264 occurs without any mutations in the immedi-
ate vicinity of the epitope (Table III). In each case the p24
sequence, or the available segment of p24 sequence, is sub-
type A. CI51 and HIV90CF402 viruses both differ by .20
amino acids across p24 from the consensus B subtype se-
quence. The AF006924 sequence differs from consensus B
subtype sequence by 14 amino acids out of the 131 amino
acids of sequence available for analysis. It may be that some
of these amino acid substitutions in subtype A p24 allow
K264 to be accommodated more easily than in subtype B
p24. Furthermore, one of these viruses (HIV90CF402) had
been extensively passaged in vitro including through chim-
panzee cells, before sequencing. This prolonged period of
laboratory adaptation may allow mutations that may not be
advantageous in vivo to persist. In subtype O viruses, and
in some untyped viruses, R264K is a common variant;
however, it is associated with other mutations such as
V267I, K263R, and usually with D260E (Table III). Taken
together, these observations support the concept that se-
quence constraints, imposed by the necessity to maintain
the structure of p24 require several changes to support an
escape virus. Thus, escape from the immunodominant
HLA-B27–restricted CTL response may require a particular
array of mutations. This could account for the delayed ap-
pearance of HIV-1 escape mutations in most cases.
R264G does not appear in the Los Alamos database.
This mutation is probably disadvantageous in isolation. It
may also indicate that in vivo the mutation is only tolerable
in subtype B viruses, all of which on the database have
E260, when E260D and R264G mutations occur in the
presence of L268. Such requirements may explain why this
mutation occurs infrequently. The observation that the
R264G mutation can be tolerated by the laboratory-
adapted LAI strain in vitro in the presence of E260 (14)
would argue that E260D is not an absolute requirement for
the viability of R264G. However, the growth require-
ments of a mutant laboratory adapted strain of virus grown
in isolation in vitro are likely to be different from in vivo
requirements where a mutant must out compete all other
strains to become dominant. The advantage of this dual
mutation may only need to be small, as even minor en-
hancements of viral fitness can quickly lead to replacement
of the less fit variants in a population (46). Standard in vitro
culture techniques do not permit the definition of small
differences in viral fitness that are revealed by viral compe-
tition and selective pressure (47, 48).
Further evidence that CTLs exert selective pressure on
these escape mutations comes from the observation that
when CTLs are absent and there is escalating viral replica-
tion, as in patient 007, the detectable virus partially reverts
to w/t. Phylogenetic analysis suggests that although some
of this recrudescence of w/t virus is derived from sequences
laid down as provirus, other reversions arise de novo and
do so in a manner where mutations occur in a certain or-
der; that is, L268M appears to occur after reversion of
K264R. This phenomenon of reversion on removal of se-
lective pressure is reminiscent of the changes seen in drug
resistant strains on drug cessation (49–52).
When antiretroviral therapy fails to control HIV replica-
tion well, evolution of the virus can continue. When ther-
apy is effective proviral evolution appears to be slowed sub-
stantially (53), and sequences tend to reflect the virus
population that was present when therapy started. The fact
that an escape mutant can persist for many months after the
initiation of therapy has therapeutic implications; any cessa-
tion or failure of therapy will result inevitably in recrudes-
cence of a virus containing immune escape variants.
The exact causes of disease progression in HIV infection
are still poorly understood. However, the analysis presented
here and accumulating evidence from other work (3–8)
strengthens the early suggestion (54) that evasion of the
CTL response through mutation of the virus is a significant
mechanism of viral persistence.
Figure 3. Ribbon diagrams of structure of NH2-terminal domain of
p24 adapted from reference 41. Helix 7 is shown in blue, residues 260,
264, and 268 are highlighted in green, yellow, and red, respectively. (a)
The structure of the monomer. (b) The structure of the dimer in the crys-
tal structure, highlighting the role that residues 260, 264, and 268 play in
one interface; in this diagram these residues are shown in the “space fill”
convention.
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